Henlius operates 3 manufacturing facilities with a current total commercial production capacity of 48,000L and maintains stable supply in China, Southeast Asia, Europe, MIDE and Latin America.
Covering a total area of about 11,000 m2, the Xuhui Facility in Shanghai has a total capacity of 24,000L. The facility and its accompanying quality management systems have passed on-site inspections and audits conducted by the NMPA, EMA, PIC/S participating members Indonesia’s BPOM and Brazil’s ANVISA, the European United (EU) QP and international commercial partners.
Henlius later opened its Songjiang I plant with a commercial capacity of 24,000L, and is GMP-certificated by China, the EU and the US regulatory agencies.
A third manufacturing plant, Songjiang II is also in development. Covering about 130,000 square meters (200mu) and also in Shanghai, Songjiang II will be one of the largest biologic medicine manufacturing facilities in China once completed. The facility strictly follows international GMP standards and adopts new technologies (continuous flow technology etc.) to align with the design criteria of biomedical automation, information, and intelligence. The first and second phase total capacity for Songjiang II will reach 36,000L.
Henlius was among the first in China to adopt single-use manufacturing technologies, particularly single-use bioreactors. The company continues to pioneer continuous manufacturing processes and, in 2021, established China’s first end-to-end continuous manufacturing pilot plant. Henlius actively implements Business Intelligence (BI) systems to enable real-time monitoring of key production, quality, and supply chain indicators, along with visualized risk forecasting. The company also promotes the localization and optimization of critical production materials and consumables, continuously enhancing operational sustainability.
